Impact of New-Onset Conduction Disturbances following Transcatheter Aortic Valve Replacement on Outcomes: A Single-Center Study
Table 1
Baseline and procedural characteristics.
Overall
Persistent
Nonpersistent
values
N = 337
N = 150
N = 187
Age (year)
81.7 ± 7.8 (337)
81.8 ± 8.4 (150)
81.6 ± 7.3 (187)
0.55
Male (sex)
178/337 (52.8%)
88/150 (58.7%)
90/187 (48.1%)
0.054
Body mass index (kg/m2)
29.28 ± 6.71 (336)
29.85 ± 7.35 (150)
28.82 ± 6.14 (186)
0.34
Hypertension
298/337 (88.4%)
129/150 (86.0%)
169/187 (90.4%)
0.21
Diabetes
117/337 (34.7%)
57/150 (38.0%)
60/187 (32.1%)
0.26
Chronic obstructive pulmonary disease
77/336 (22.9%)
29/149 (19.5%)
48/187 (25.7%)
0.48
Prior myocardial infarction
78/335 (23.3%)
35/148 (23.6%)
43/187 (23.0%)
0.89
Atrial fibrillation/flutter
121/335 (36.1%)
57/149 (38.3%)
64/186 (34.4%)
0.47
Prior conduction disturbance
121/335 (36.1%)
72/150 (48.0%)
49/185 (26.5%)
<0.001
NYHA functional class III/IV
282/336 (83.9%)
129/150 (86.0%)
153/186 (82.3%)
0.35
Carotid stenosis
46/332 (13.9%)
13/148 (8.8%)
33/184 (17.9%)
0.02
Unilateral
24/332 (7.2%)
8/148 (5.4%)
16/184 (8.7%)
0.25
Bilateral
22/332 (6.6%)
5/148 (3.4%)
17/184 (9.2%)
0.03
Prior stroke
24/337 (7.1%)
8/150 (5.3%)
16/187 (8.6%)
0.25
Prior percutaneous coronary intervention
110/337 (32.6%)
57/150 (38.0%)
53/187 (28.3%)
0.06
Prior coronary artery bypass grafting
57/336 (17.0%)
26/150 (17.3%)
31/186 (16.7%)
0.87
Prior transient ischemic attack
20/336 (6.0%)
8/150 (5.3%)
12/186 (6.5%)
0.67
Peripheral arterial disease
86/337 (25.5%)
42/150 (28.0%)
44/187 (23.5%)
0.35
Left ventricular ejection fraction (%)
59.0 ± 12.4 (333)
56.0 ± 12.5 (147)
61.4 ± 11.8 (186)
<0.001
<30%
9/333 (2.7%)
4/147 (2.7%)
5/186 (2.7%)
1.00
30–45%
38/333 (11.4%)
25/147 (17.0%)
13/186 (7.0%)
0.004
45–55%
33/333 (9.9%)
21/147 (14.3%)
12/186 (6.5%)
0.02
≥55%
253/333 (76.0%)
97/147 (66.0%)
156/186 (83.9%)
<0.001
Glomerular filtration rate (mL/min)
61.1 ± 36.4 (333)
62.0 ± 45.5 (148)
60.3 ± 27.2 (185)
0.39
STS score PROM (%)
6.40 ± 3.87 (305)
6.53 ± 3.90 (135)
6.30 ± 3.86 (170)
0.62
5-meter walk test, sec
8.23 ± 2.58 (251)
8.60 ± 2.70 (108)
7.96 ± 2.46 (143)
0.03
Device type
Self-expanding
169/337 (50.1%)
71/150 (47.3%)
98/187 (52.4%)
0.36
Corevalve
38/337 (11.3%)
17/150 (11.3%)
21/187 (11.2%)
0.98
Evolut pro
74/337 (22.0%)
30/150 (20.0%)
44/187 (23.5%)
0.44
Evolut R
57/337 (16.9%)
24/150 (16.0%)
33/187 (17.6%)
0.69
Balloon expandable
168/337 (49.9%)
79/150 (52.7%)
89/187 (47.6%)
0.36
SAPIEN
29/337 (8.6%)
13/150 (8.7%)
16/187 (8.6%)
0.97
SAPIEN 3
122/337 (36.2%)
58/150 (38.7%)
64/187 (34.2%)
0.40
SAPIEN XT
17/337 (5.0%)
8/150 (5.3%)
9/187 (4.8%)
0.83
Elective
302/336 (89.9%)
131/150 (87.3%)
171/186 (91.9%)
0.16
Transfemoral access
301/335 (89.9%)
133/149 (89.3%)
168/186 (90.3%)
0.75
Moderate sedation
208/336 (61.9%)
88/150 (58.7%)
120/186 (64.5%)
0.27
Discharge medication: antiplatelet agent (aspirin or P2Y12)
305/337 (90.5%)
132/150 (88.0%)
173/187 (92.5%)
0.16
Discharge medication: antithrombic agent (dabigatran, warfarin, factor Xa inhibitor)
100/337 (29.7%)
43/150 (28.7%)
57/187 (30.5%)
0.72
Device success
329/336 (97.9%)
147/149 (98.7%)
182/187 (97.3%)
0.47
Implantation success†
328/334 (98.2%)
145/150 (96.7%)
183/184 (99.5%)
0.09
Values are n/N (%) or mean ± standard deviation. NYHA = New York Heart Association; PROM = predicted risk of mortality; STS = Society of Thoracic Surgeons. Defined as successful vascular access, delivery, and deployment of a single device in the proper anatomic location, appropriate performance of the prosthetic heart valve (aortic valve area >1.2 cm2 and mean aortic valve gradient <20 mm Hg or peak velocity <3 m/s without moderate or severe prosthetic valve aortic regurgitation), and successful retrieval of the delivery system. †Defined as correct positioning of a single device in the proper anatomical location.
